Drug Trial Radar · NCT03684694
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
136
Actual
Start
Dec 1, 2018
Primary completion
Nov 8, 2022
Study completion Nov 8, 2022
Sponsor
- Lead sponsor
- ADC Therapeutics S.A.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.
Conditions
- Diffuse Large B-Cell Lymphoma
- Mantle Cell Lymphoma
Interventions
Loncastuximab TesirineDrug
Intravenous (IV) infusion.
IbrutinibDrug
Oral capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 until 30 days after last dose; max duration of treatment was 686 days for Phase 1 (up to approximately 716 days total)
- Phase 1: Number of Participants With Serious TEAEsTime frame: Day 1 until 30 days after last dose; max duration of treatment was 686 days for Phase 1 (up to approximately 716 days total)
- Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: 21 days
- Phase 1: Number of Participants With Dose InterruptionsTime frame: Up to a maximum of 686 days
- Phase 1: Number of Participants With Dose ReductionsTime frame: Up to a maximum of 686 days
- Phase 2: Complete Response Rate (CRR)Time frame: Up to approximately 38 months
Locations
35 sites in 6 countries. Site status is shown where the registry gives one.
University of California Irvine Health Chao Family Comprehensive Cancer Center
Orange, California
Redlands Community Hospital
Redlands, California
University of Miami
Miami, Florida
Miami Cancer Institute
Miami, Florida
The Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia
Georgia Cancer Center at Augusta University
Augusta, Georgia
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
Saint Vincent Healthcare
Billings, Montana
Case Western Reserve University
Cleveland, Ohio
GasthuisZusters Antwerpen Sint-Augustinus
Wilrijk, Belgium
CHU UCL Namur (Site Godinne)
Yvoir, Belgium
Centre Hospitalier Universitaire de Rennes Hôpital Pontchailou
Bretagne, France
Hôpital Hôtel-Dieu
Loiré, France
Hôpital Saint-Eloi
Montpellier, France
Hôpital Saint-Louis
Paris, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Centre Hospitalier Universitaire De Poitier - Hopital De La Miletrie - Hopital Jean Bernard
Poitiers, France
Azienda Ospedaliera Pap Giovanni XXIII
Bergamo, Italy
Policlinico Sant'Orsola Malpighi
Bologna, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Brescia, Italy
Istituto Scientifico Rmagnolo per lo Studio e la Cura dei Tumori
Meldola FC, Italy
Istituto Europeo di Oncologia
Milan, Italy
Azienda Unita Sanitaria Locale de Ravenna
Ravenna, Italy
IRCCS istituto Clinico Humanitas U.O. di Oncologia ed Ematologia
Via Manzoni, Rozzano, Italy
Hospital Universitario Vall d'Hebrón
Barcelona, Spain
Hospital Duran I Reynals
Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
The Christie NHS Foundation Trust
Manchester, United Kingdom
Abertawe Bro Morgannwg University Health Board
Swansea, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.